振动网孔雾化器吸入肺表面活性物质联合经鼻持续气道正压治疗新生儿呼吸窘迫综合征的疗效与安全性
该前瞻性研究纳入2020年12月至2021年6月蚌埠医学院第一附属医院收治的42例RDS早产儿,随机分为振动网孔雾化技术组(20例)和INSURE技术组(22例),两组均接受NCPAP联合PS治疗。给药1小时后两组血气分析和PaO2/FiO2均显著改善,振动网孔雾化组PaO2/FiO2改善更明显(198±34 vs. 173±39 mmHg,P<0.05),呼吸支持时间更短(96±13 vs. 120±18小时,P<0.01),MVET需求率、PS二次使用率、BPD及其他并发症发生率无统计学差异,两组均无死亡及气胸、肺出血等严重不良事件。作者认为该技术有效安全,值得临床推广应用。
要点
- RDS早产儿给予NCPAP联合振动网孔雾化吸入PS后1小时,PaO2/FiO2改善程度优于INSURE组(198±34 vs. 173±39 mmHg,P<0.05)。
- 振动网孔雾化组呼吸支持时间显著短于INSURE组(96±13 vs. 120±18小时,P<0.01)。
- 两组MVET需求率无统计学差异[5.0%(1/20)vs. 13.6%(3/22),P>0.05]。
- 振动网孔雾化组PVH-IVH发生率低于INSURE组[0%(0/20)vs. 18.2%(4/22)],但无统计学差异(P>0.05)。
- 两组均无死亡及气胸、肺出血、PVL、ROP、NEC等严重不良事件。
适用人群与场景
- 2020年12月至2021年6月蚌埠医学院第一附属医院收治的RDS早产儿,最终纳入42例(振动网孔雾化组20例,INSURE组22例)。
处置流程与药物剂量
- 两组均接受NCPAP联合PS治疗;振动网孔雾化组通过新型振动网孔雾化技术将PS吸入肺内,INSURE组通过气管内导管将PS注入肺内。
研究设计与关键结果
- 前瞻性研究,最终纳入42例RDS早产儿,随机分为振动网孔雾化技术组(20例)和INSURE技术组(22例)。
- 给药前两组血气分析和PaO2/FiO2无显著差异;给药1小时后两组血气分析和PaO2/FiO2均显著改善。
- 给药1小时后振动网孔雾化组PaO2/FiO2改善优于INSURE组[198±34 vs. 173±39 mmHg,P<0.05],两组pH值和PaCO2无显著差异。
- 振动网孔雾化组呼吸支持时间显著短于INSURE组(96±13 vs. 120±18小时,P<0.01)。
- 两组MVET需求率无统计学差异[5.0%(1/20)vs. 13.6%(3/22),P>0.05]。
- 振动网孔雾化组PVH-IVH发生率低于INSURE组[0%(0/20)vs. 18.2%(4/22)],但无统计学差异(P>0.05)。
- 两组PS二次使用率[5.0%(1/20)vs. 9.1%(2/22)]和BPD发生率[5.0%(1/20)vs. 4.5%(1/22)]及其他并发症发生率均无显著差异(均P>0.05)。
- 两组均无死亡及气胸、肺出血、PVL、ROP、NEC等严重不良事件。
证据类型、等级与局限
- 证据类型:前瞻性随机对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与INSURE技术相比,NCPAP联合振动网孔雾化技术在治疗RDS中同样有效且安全,可显著改善PaO2/FiO2并缩短呼吸支持时间,值得临床推广应用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the efficacy and safety of nasal continuous positive airway pressure (NCPAP) combined with inhalation of pulmonary surfactant (PS) using vibrating mesh nebulizers in the treatment of neonatal respiratory distress syndrome (RDS).
METHODS: A prospective study was performed on premature infants with RDS admitted to the First Affiliated Hospital of Bengbu Medical College between December 2020 and June 2021. They were randomly assigned into vibrating mesh atomization technology group and intubation-surfactant-extubation (INSURE) technology group. The two groups were treated with NCPAP combined with PS. PS in the vibrating mesh atomization technology group was inhaled into the lungs by the new vibrating mesh atomization technology, while PS in the INSURE group was injected into the lungs by endotracheal tube. The pH value, arterial partial pressure of carbon dioxide (PaCO2), oxygenation index (PaO2/FiO2), mechanical ventilation via endotracheal tube (MVET) demand rate, duration of respiratory support, secondary use of PS, complications, and hospital mortality were compared between the two groups. The occurrences of adverse events in the two groups were recorded.
RESULTS: A total of 42 preterm infants were finally enrolled, including 20 cases in the vibrating mesh atomization technology group and 22 cases in the INSURE technology group. There were no significant differences in blood gas analysis and PaO2/FiO2 before PS administration between the two groups. One hour after PS administration, blood gas analysis and PaO2/FiO2 were significantly improved in both groups. Compared with the INSURE technology group, the improvement of PaO2/FiO2 was more obvious in the vibrating mesh atomization technology group [mmHg (1 mmHg≈0.133 kPa): 198±34 vs. 173±39, P < 0.05], but no significant difference in pH value or PaCO2 was found between the two groups. The duration of respiratory support in the vibrating mesh atomization technology group was significantly shorter than that in the INSURE technology group (hours: 96±13 vs. 120±18, P < 0.01), but there was no statistical difference in MVET demand rate [5.0% (1/20) vs. 13.6% (3/22), P > 0.05]. The incidence of periventricular-intraventricular hemorrhage (PVH-IVH) in the vibrating mesh atomization technology group was less than that in the INSURE technology group [0% (0/20) vs. 18.2% (4/22)], but no statistical difference was found (P > 0.05). No significant differences in the secondary use rate of PS and incidence of bronchopulmonary dysplasia (BPD) or other complications were found between the vibrating mesh atomization technology group and the INSURE technology group [5.0% (1/20) vs. 9.1% (2/22), 5.0% (1/20) vs. 4.5% (1/22), both P > 0.05]. There were no deaths or serious adverse events such as pneumothorax, pulmonary hemorrhage, periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), and necrotizing enterocolitis (NEC) in both groups.
CONCLUSIONS: Compared with the INSURE technique, NCPAP combined with vibrating mesh atomization technology was also effective and safe in the treatment of RDS, which could significantly improve PaO2/FiO2 and shorten the duration of respiratory support. Thus, it was worthy of clinical popularization and application.
参考来源
- Gao Y, Chen X, Zhang Z, et al. [Efficacy and safety of inhalation of pulmonary surfactant using vibrating mesh nebulizers combined with nasal continuous positive airway pressure in the treatment of neonatal respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35307066. doi:10.3760/cma.j.cn121430-20210602-00815
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。